secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0000950170-23-028281
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics annual meeting results: all proposals approved
----------------------------------------------------------------

- 19,500,381 shares present (≈60% of outstanding); quorum met.
- Elected Class III directors Palasis (16.4M for), Smith (16.3M for), Tobin (16.6M for).
- Ratified BDO USA as independent auditor for FY 2023 (9.5M for, 8K against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023028281/0000950170-23-028281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023028281/lyra-20230613.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-028281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer